Latest News

Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation Condition: Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic Intervention: Drug: ipatasertib Drug: Atezolizumab Purpose: This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to […]

Somatic inactivating variants in the gene CDK12, encoding cyclin-dependent kinase 12, generate fusion-induced neoantigens in prostate cancer. This finding supports the hypothesis that prostate cancers with variant CDK12 will have a response to checkpoint inhibitor drugs. The New England journal of medicine. 2018 Sep 13 [Epub] Emmanuel S Antonarakis From the Johns Hopkins University Sidney Kimmel Comprehensive Cancer […]

Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) Condition: Metastatic Castration Resistant Prostate Cancer Intervention: Drug: Pembrolizumab Drug: 177Lu-PSMA Purpose: This investigator driven study will examine the safety, tolerability and efficacy of the combination of 177Lutetium-PSMA (177Lu-PSMA) and pembrolizumab in patients with metastatic […]

{{header-clinical-trials-navigation}} PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03635866 Sponsor: NYU Langone Health Eligibility: Age: minimum 18 Years maximum 100 Years Gender: Male Inclusion Criteria: The participant has undergone MRFTB […]

Non-metastatic castration resistant prostate cancer (M0CRPC) is a heterogenous disease state affecting an estimated 100,000 men in the United States. Development of more sensitive modalities for detection of metastasis has altered the landscape of advanced prostate cancer, but M0CRPC has remained a condition that previously lacked FDA-approved treatment. The emerging data on new generation Androgen […]

Men who are survivors of prostate cancer report a variety of psychological and physical factors contributing to a lower quality of life, and physical activity can assist to mitigate these issues. This review aims to provide a summary of physical activity behaviour change trials targeting prostate cancer survivors, assess the feasibility of these interventions and, […]

This study aimed to determine, in men recently diagnosed with grade group 1 (GG1) prostate cancer, if magnetic resonance imaging (MRI) with targeted biopsy could identify a greater proportion of men with GG ≥2 cancer on their confirmatory biopsy compared with systematic biopsies. The study was registered with www.clinicaltrials.gov (NCT01354171). This study is a prospective, […]

The Stephenson nomogram is widely used to estimate the success of salvage radiotherapy (sXRT) for prostate cancer (PCa) recurrence after radical prostatectomy (RP). To determine whether multiparametric pelvic magnetic resonance imaging (mpMRI) performed for biochemical recurrence after RP improves prognostication of sXRT relative to the Stephenson nomogram. Men undergoing RP at our institution from 2003 […]

Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control the development of CRPC remains an unmet clinical need. The well-established dependency of cancer cells on the tumour microenvironment indicates that the microenvironment might control the emergence of […]

AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests that AR-V7-positive tumors may be enriched for DNA-repair defects, perhaps rendering them more sensitive to immune-checkpoint blockade. We enrolled 15 metastatic prostate cancer patients with AR-V7-expressing circulating tumor cells into a prospective phase-2 trial. Patients […]